Prostate Cancer and Prostatic Diseases

Article	Citations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	134
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	106
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions	104
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	90
Best of 2022 in prostate cancer and prostatic diseases	75
New BPH therapy classification: what really FITs?	71
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	63
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	59
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	58
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	54
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes	45
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study	44
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	43
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	43
Concerns regarding prostate cancer screening guidelines in minority populations	42
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study	41
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis	40
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	39
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	39
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer	37
Feasibility and safety study of the Flostent™ system (RAPID-I)	37
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	36
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study	36
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	35
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer	35

Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	34
TRexit is going one step further	33
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	33
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	32
Incidence of prostate cancer in transgender women in the US: a large database analysis	32
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients	32
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons	31
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	30
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	30
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer	29
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	29
“Targeted microwave ablation: another way to kick the can(cer) down the road?”	27
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	27
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials	27
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants	26
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	25
Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy	25
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort	24
Antimicrobial prophylaxis: To do or not to do? This is the question	24
The times have changed. Let the urologists change!	24
A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care	23
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	23
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision	23
Prostate biopsy - current discussions and future perspectives	23
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study	23
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction	23
The effects of glycemic index on prostate cancer progression in a xenograft mouse model	22
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells	22
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate	22
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	22
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	22
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	22
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT	21
Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!	21
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK	21
Association of prostate cancer with human papillomavirus infections: a case-control study	21
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey	21
Prognostic value of MR visibility/invisibility in men on Active Surveillance	20
Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	20
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis	20
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer	20
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy	19
Perioperative outcomes comparing the DaVinci 5 with DaVinci Xi in patients undergoing robotic-assisted radical prostatectomy	19
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification	19
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan	19
Re: Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	18
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	18
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials	18
Sleep disturbances are underappreciated in prostate cancer survivorship	18
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer	18

Response to correspondence regarding “The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study”	18
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial	18
Risk calculators for the detection of prostate cancer: a systematic review	18
Practical management of hematuria after endoscopic surgery for benign prostatic obstruction	18
Cardiovascular risk in ADT recipients: does the type of ADT matter?	17
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications	17
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	17
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?	17
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review	17
Less is more: the “Safety Net Approach” balances precision and safety	17
Characteristics of incidental prostate cancer in the United States	16
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy	16
Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI	15
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study	15
5 T versus 3 T MRI for prostate cancer: an intra-individual prospective comparison of image quality and diagnostic performance	15
Negative perceptions of the health system and racial inequities in PSA screening	15
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis	15
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores	15
Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis	15
The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis	15
Prevalence and determinants of shared decision-making for PSA testing in the United States	15
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey	15
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	15
Focal therapy for localized prostate cancer: not all that glitters is gold	14
Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia	14
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	14
Feasibility and safety of single-port transvesical simple prostatectomy in patients with very large prostates: A volume-stratified analysis	14
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	13
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	13
Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis	13
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	13
The impact of race on survival in metastatic prostate cancer: a systematic literature review	13
Best of 2023 in Prostate Cancer and Prostatic Diseases	13
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	13
Bridging the gap between PSMA-PET and reality: critical missing elements in AR-guided pelvic lymph node dissection	13
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	12
Biopsy strategies in the era of mpMRI: a comprehensive review	12
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?	12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	12
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer	12
Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis	12
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	12
Overcoming barriers to prostate cancer genetic testing: who, when, and how	12
Interpreting undetectable PSA and surveillance inference in post hoc ARAMIS analyses	12
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz	12
Hyperglycemia and microRNAs in prostate cancer	12
Quality of information and appropriateness of ChatGPT outputs for urology patients	12
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients	12
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	12
The changing face of castrate resistant prostate cancer	12
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta	12
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH	11
Quality of information and appropriateness of Open AI outputs for prostate cancer	11
Surveillance after Focal Therapy – a Comprehensive Review	11
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	11
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment	11
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry	11
MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?	11
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration	11
The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study	11
Exploring the utility of artificial intelligence in identifying progression of prostate cancer during active surveillance: A systematic review	11
Fecal incontinence after prostate cancer irradiation: a systematic literature review	11
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study	11
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer	11
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis	11
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study	11
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016	10
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer	10
15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer	10
Social determinants of health into evaluations of quality and appropriateness of AI assistant ChatGPT	10
Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	10
Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer	10
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care	10
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer	10
Whack-a-met: serial SABR for repeated oligoprogression in metastatic CRPC	10
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	10
Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS	10
Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores	9
Best of 2024 in Prostate Cancer and Prostatic diseases	9
Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis	9

Characterisation of cell lines derived from prostate cancer patients with localised disease	9
AI-aided diagnostic performance for prostate MRI: systematic review and meta-analysis	9
Impact of transperitoneal anterior, retzius-sparing, extraperitoneal, transvesical and perineal approaches on urinary continence recovery after robot-assisted radical prostatectomy: a systematic revie	9
MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in i	9
Quality of information and appropriateness of ChatGPT outputs for urology patients	9
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	9
Relative search popularity of five advanced prostate cancer medications using Google Trends	9
Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients	9
Re: Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP	9
New robotic platforms for prostate surgery: the future is now	9
Concerns regarding the methodological limitations of the OASIS study	9
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis	9
Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study	9
Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis	9
Racial variation in the advanced prostate cancer genome	8
Integrating clinical and technological perspectives to enhance predictive modeling in prostate cancer surgery	8
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlle	8
Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates	8
Transperineal laser ablation in the management of benign prostatic hyperplasia: an updated systematic review and pooled analysis	8
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer	8
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer	8
Advancing the treatment of localized prostate cancer with MR-guided radiotherapy	8
Letter: The Hawthorne effect—behavioral changes from research observation—as confounder and mediator in the ERASE trial	8
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis	8
Role of targeted biopsy, perilesional biopsy, random biopsy, and their combination in the detection of clinically significant prostate cancer by mpMRI/transrectal ultrasonography fusion biopsy in conf	8
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab	8
Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis	8
Prostate cancer screening in Europe: future directions and perspectives	8
Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localised prostate cancer—a systematic review and meta-analysis	8
Targeted and perilesional biopsy: triumphs and cautions	8
Insights gained from single-cell transcriptomics on the cellular identity and plasticity of prostate epithelial cells	8
Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis	8
Comparative analysis of robot-assisted simple prostatectomy: the HUGO™ RAS system versus the DaVinci® Xi system	8
Thulium fiber laser versus holmium MOSESTM laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized prospective clinical study	8
The times they are (still) a-Changin’	7
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	7
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	7
Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients	7
Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis	7
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy	7
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men	7
Artificial intelligence applications in prostate cancer	7
A Visual Standardized (ViSta) map integrating imaging (MRI), biopsy findings and Specimen Prostate Cancer location	7
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors	7
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies	7
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board	7
Head-to-head comparison of DaVinci and Hugo™ RAS robotic platforms for robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies	6
Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia	6
Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies	6
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide	6
Publisher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer	6
Editorial: Advancing external beam radiotherapy—and rediscovering what brachytherapy already provides?	6
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading	6
Short term results after minimally invasive treatments for benign prostatic enlargement: the first randomized trial comparing transperineal laser ablation and water vapor ablation	6
Prostate cancer in New York City: impact of neighborhood level social determinants of care	6
Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?	6
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes	6
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or	6
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	6
Comparison of senhance and da vinci robotic radical prostatectomy: short-term outcomes, learning curve, and cost analysis	6
Setting new standards: robot-assisted radical prostatectomy as a day case	6
Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark	6
Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages—dependence on GPR120	6
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany	6
Urinary microbiota and prostatic diseases: the key for the lock? A systematic review	6
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial	6
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data	5
Correction: Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men	5
Fatty acid diet and prostate cancer: a treasure hunt or a wild goose chase?	5
ExoDx test for prostate cancer: the future is liquid—Editorial Comment	5
Primary bladder neck obstruction in men—new perspectives in physiopathology	5
Mitochondrial dysfunction in urologic disease	5
Relationship between cigarette use and prostate cancer risk: what do we know and what should we do?	5
Clinical and surgical management of recto-urinary fistula after radical prostatectomy: a systematic review on current evidence	5
External validation of an algorithm to personalize nerve sparing approaches during robot-assisted radical prostatectomy in men with unilateral high-risk prostate cancer	5
Prostatic stents: a systematic review and analysis of functional outcomes and complication rate	5
Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis	5
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer	5
Body composition as a determinant of the therapeutic index with androgen signaling inhibition	5
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer	5
Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men	5
Perspective transition from transrectal to transperineal MRI-fusion biopsy under local anesthesia – the institutional TREXIT learning curve of the new gold standard	5
Letter to the editor: “Incidence of prostate cancer in transgender women in the US: a large database analysis.”	5
Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures	5
Salvage treatments after focal therapy for prostate cancer – a comprehensive review	5
Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer	4
Perilesional sampling: the new standard for imaging-targeted prostate biopsies?	4
Disparities in prostate cancer diagnosis and management: recognizing that disparities exist at all junctures along the prostate cancer journey	4
Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review	4
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis	4
Reply to: Fact, overdiagnosis cannot be evaluated by comparing histological grading of prostate biopsy to prostatectomy specimen	4
A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes	4
Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies	4
Re: Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis	4
Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience	4